Galena Biopharma provides product pipeline update at ASCO annual meeting
Galena Biopharma announced two publications at the American Society of Clinical Oncologists, or ASCO, Annual Meeting taking place May 31-June 4 in Chicago, Illinois. The company also provided an update on the ongoing Folate Binding Protein Phase 1/2 clinical trial. The study concluded that in completed phase 1/2 trials of NeuVax, patients who exhibit robust in vitro IR have lower recurrence rates. This finding suggests that nelipepimut-specific CTL clonal expansion is a valid biomarker for CR in patients treated with NeuVax. In the SN-33 trial, the 60-month Landmark Analysis demonstrated a 5.6% recurrence rate with NeuVax vs. a 25.9% recurrence rate in the control arm--a recurrence reduction of 78.4%.